Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions - PubMed (original) (raw)
Review
. 2019 Apr;71(2):198-224.
doi: 10.1124/pr.118.015768.
Affiliations
- PMID: 30890566
- DOI: 10.1124/pr.118.015768
Review
Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions
Gerard Clarke et al. Pharmacol Rev. 2019 Apr.
Abstract
The microbiome plays a key role in health and disease, and there has been considerable interest in therapeutic targeting of the microbiome as well as mining this rich resource in drug discovery efforts. However, a growing body of evidence suggests that the gut microbiota can itself influence the actions of a range of xenobiotics, in both beneficial and potentially harmful ways. Traditionally, clinical studies evaluating the pharmacokinetics of new drugs have mostly ignored the important direct and indirect effects of the gut microbiome on drug metabolism and efficacy. Despite some important observations from xenobiotic metabolism in general, there is only an incomplete understanding of the scope of influence of the microbiome specifically on drug metabolism and absorption, and how this might influence systemic concentrations of parent compounds and toxic metabolites. The significance of both microbial metabolism of xenobiotics and the impact of the gut microbiome on host hepatic enzyme systems is nonetheless gaining traction and presents a further challenge in drug discovery efforts, with implications for improving treatment outcomes or counteracting adverse drug reactions. Microbial factors must now be considered when determining drug pharmacokinetics and the impact that an evolving and dynamic microbiome could have in this regard. In this review, we aim to integrate the contribution of the gut microbiome in health and disease to xenobiotic metabolism focusing on therapeutic interventions, pharmacological drug action, and chemical biotransformations that collectively will have implications for the future practice of precision medicine.
Copyright © 2019 The Author(s).
Similar articles
- Connecting the dots: Targeting the microbiome in drug toxicity.
Luo Y, Zhou T. Luo Y, et al. Med Res Rev. 2022 Jan;42(1):83-111. doi: 10.1002/med.21805. Epub 2021 Apr 15. Med Res Rev. 2022. PMID: 33856076 Review. - Chemical Metabolism of Xenobiotics by Gut Microbiota.
Nakov R, Velikova T. Nakov R, et al. Curr Drug Metab. 2020;21(4):260-269. doi: 10.2174/1389200221666200303113830. Curr Drug Metab. 2020. PMID: 32124693 Review. - Chemical transformation of xenobiotics by the human gut microbiota.
Koppel N, Maini Rekdal V, Balskus EP. Koppel N, et al. Science. 2017 Jun 23;356(6344):eaag2770. doi: 10.1126/science.aag2770. Science. 2017. PMID: 28642381 Free PMC article. Review. - Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
Swanson HI. Swanson HI. Drug Metab Dispos. 2015 Oct;43(10):1499-504. doi: 10.1124/dmd.115.065714. Epub 2015 Aug 10. Drug Metab Dispos. 2015. PMID: 26261284 Free PMC article. Review. - Human Gut Microbiota and Drug Metabolism.
Pant A, Maiti TK, Mahajan D, Das B. Pant A, et al. Microb Ecol. 2023 Jul;86(1):97-111. doi: 10.1007/s00248-022-02081-x. Epub 2022 Jul 23. Microb Ecol. 2023. PMID: 35869999 Free PMC article. Review.
Cited by
- Maternal probiotic supplementation protects against PBDE-induced developmental, behavior and metabolic reprogramming in a sexually dimorphic manner: Role of gut microbiome.
Denys ME, Kozlova EV, Liu R, Bishay AE, Do EA, Piamthai V, Korde YV, Luna CN, Lam AA, Hsiao A, Currás-Collazo M. Denys ME, et al. Arch Toxicol. 2024 Nov 9. doi: 10.1007/s00204-024-03882-4. Online ahead of print. Arch Toxicol. 2024. PMID: 39520540 - Effects of Propolis Supplementation on Gut Microbiota and Uremic Toxin Profiles of Patients Undergoing Hemodialysis.
Fonseca L, Ribeiro M, Schultz J, Borges NA, Cardozo L, Leal VO, Ribeiro-Alves M, Paiva BR, Leite PEC, Sanz CL, Kussi F, Nakao LS, Rosado A, Stenvinkel P, Mafra D. Fonseca L, et al. Toxins (Basel). 2024 Sep 25;16(10):416. doi: 10.3390/toxins16100416. Toxins (Basel). 2024. PMID: 39453192 Free PMC article. Clinical Trial. - Advancements in enzymatic reaction-mediated microbial transformation.
Zheng CC, Gao L, Sun H, Zhao XY, Gao ZQ, Liu J, Guo W. Zheng CC, et al. Heliyon. 2024 Sep 20;10(19):e38187. doi: 10.1016/j.heliyon.2024.e38187. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39430465 Free PMC article. Review. - Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy.
Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, Ruiz-Pozo VA, Tamayo-Trujillo R, Cabrera-Andrade A, Zambrano AK. Guevara-Ramírez P, et al. Int J Mol Sci. 2024 Sep 24;25(19):10255. doi: 10.3390/ijms251910255. Int J Mol Sci. 2024. PMID: 39408584 Free PMC article. Review. - Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model.
Oguri N, Miyoshi J, Nishinarita Y, Wada H, Nemoto N, Hibi N, Kawamura N, Miyoshi S, Lee STM, Matsuura M, Osaki T, Hisamatsu T. Oguri N, et al. NPJ Biofilms Microbiomes. 2024 Sep 16;10(1):81. doi: 10.1038/s41522-024-00564-y. NPJ Biofilms Microbiomes. 2024. PMID: 39285193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources